Ocular Therapeutix (OCUL) Operating Leases (2019 - 2026)

Ocular Therapeutix has reported Operating Leases for 8 years, with the latest figure at $3.5 million in Q2 2026.

• Operating Leases for Q2 2026 came in at $3.5 million, down 21.37% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.5 million (down 21.37% YoY), and the FY2025 annual result was $2.8 million, down 47.33% from the prior year.
• Operating Leases retreated to $3.5 million in Q2 2026, from $4.2 million in the prior quarter.
• Over five years, Operating Leases peaked at $8.7 million in Q4 2022 and troughed at $2.8 million in Q4 2025.
• A 5-year average of $5.6 million and a median of $5.4 million in 2022 frame the typical range for Operating Leases.
• The widest annual swing landed in 2023, when Operating Leases surged 57.29%; it then slumped 47.33% in 2025.
• A 5-year view of Operating Leases shows it stood at $8.7 million in 2022, then fell by 20.74% to $6.9 million in 2023, then decreased by 22.29% to $5.3 million in 2024, then slumped by 47.33% to $2.8 million in 2025, then climbed by 23.13% to $3.5 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $3.5 million in Q2 2026, $4.2 million in Q1 2026, and $2.8 million in Q4 2025.